EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera
By Dominic Chopping
STOCKHOLM--EQT led a 93 million-euro ($102.5 million) Series A funding round in PanTera, a Belgian radioisotope producer.
The Swedish buyout group said Wednesday that with additional equity and debt funding, the total amount raised was 134 million euros, which will be used mainly to support the construction of a new production facility in Belgium.
PanTera was founded in 2022 to enable large-scale production of actinium-225, which is needed to enable a new class of targeted cancer treatments known as targeted alpha therapy.
Targeted alpha therapy enables localized delivery of radiation to cancer cells without harming surrounding healthy tissue.
Demand for actinium-225 is increasing rapidly as drug-development companies look to scale-up clinical trials across a range of different cancers and seek regulatory approvals, but dependable, scalable and sustainable methods for producing it are complex and require advanced nuclear infrastructure, EQT said.
This has resulted in a global shortage of the isotope and PanTera has developed a patented production method as it works to solve the shortage.
The round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV. Alongside this, particle accelerator technology provider IBA and Belgian sovereign fund SFPIM will convert into equity 7.2 million euros of convertible loans.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
September 11, 2024 02:28 ET (06:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks